05:51 PM EDT, 06/04/2024 (MT Newswires) -- Repare Therapeutics ( RPTX ) said Tuesday US regulators issued a fast-track designation for a combination of its lunresertib drug candidate with camonsertib biomarker as a prospective treatment for certain types of ovarian cancer.

Repare's lunresertib and camonsertib combination currently is in clinical trials as a potential treatment for ovarian and endometrial cancer with CCNE1 amplification or FBXW7 or PPP2R1A mutations.

Tuesday's decision by the US Food and Drug Administration follows a similar decision last year for a combination of lunresertib and camonsertib for the treatment of CCNE1 amplified, or FBXW7 or PPP2R1A mutated endometrial cancer.

Repare expects to present the data from the drug study in Q4.

Repare shares were 2.5% higher in extended session.

Price: 3.6197, Change: +0.09, Percent Change: +2.54